Long-term Humira sustains improvements in axial spondyloarthritis

16:30 EDT 16 Apr 2018 | Healio

Désirée van der Heijde
Among patients with nonradiographic axial spondyloarthritis, treatment with adalimumab provided sustained remission, with long-term clinical and functional improvements maintained through 3 years, according to findings published in Arthritis Care & Research.
The findings were the result of an open-label extension of the 12-week, phase 3 ABILITY-1 trial, the researchers wrote.
Adalimumab was effective for the treatment of patients with [nonradiographic axial spondyloarthritis (axSpA)] in the ABILITY-1 trial,” Désirée van der

Original Article: Long-term Humira sustains improvements in axial spondyloarthritis


More From BioPortfolio on "Long-term Humira sustains improvements in axial spondyloarthritis"

Quick Search


Relevant Topics

An antibody is a protein produced by the body's immune system when it detects harmful substances, called antigens. Examples of antigens include microorganisms (such as bacteria, fungi, parasites, and viruses) and chemicals. Antibodies may be produc...

Arthritis is by definition the inflammation of one or more joints, characterized by swelling, pain, warmth, redness and diminished range of joint movement (Oxford Medical Dictionary). There are many different types; Noninflammatory; Osteoarthritis, N...